Clinical Trial

GliomaAI-MG: MRI-Based Detection of Molecular Glioblastoma

Study acronym: GliomaAI-MG
Completed
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-MG can help detect a specific molecular type of brain tumour called molecular glioblastoma using routine MRI scans. The study uses previously collected and fully anonymised MRI data from 1,372 patients from 13 institutions in the Cancer Imaging Archive (TCIA). The main questions it aims to answer are: * How accurately can GliomaAI-MG identify molecular glioblastoma from MRI scans? * How well does the system perform across data from different hospitals and patient groups? Researchers will use existing MRI scans and clinical information to train and test the AI system. No new scans, treatments, or hospital visits are required for participants, and all data used is fully anonymised and obtained from an existing research database. Participants will not be asked to do anything, as this study only uses previously collected imaging data.
Trial Details
NCT Number NCT07664254
Lead Sponsor Deep Learning Institute of Radiological Sciences
Conditions Glioma, Glioma (Diagnosis), Glioblastom WHO Grade 4
Enrollment 1,372 participants
Start Date 2017-03-14
Primary Completion 2021-03-09 (estimated)
Study Completion 2021-07-16 (estimated)
Updated on ClinicalTrials.gov 2026-06-24